Skip to Content

Ombitasvir / Paritaprevir / Ritonavir Dosage

Applies to the following strength(s): 12.5 mg-75 mg-50 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Chronic Hepatitis C

2 tablets orally once a day (in the morning)

Recommended Regimen and Duration of Therapy:
-Genotype 4, without cirrhosis: Ombitasvir/paritaprevir/ritonavir and ribavirin for 12 weeks

-Before starting this drug, baseline hepatic laboratory and clinical parameters should be assessed.
-The manufacturer product information should be consulted for ribavirin dosing recommendations, including dose adjustments.
-Use of this drug without ribavirin may be considered for therapy-naive patients who cannot take or tolerate ribavirin.

Use: In combination with ribavirin, for the treatment of patients with genotype 4 chronic HCV infection without cirrhosis

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.

-If required, the manufacturer product information for ribavirin should be consulted regarding use in patients with renal dysfunction.

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate to severe liver dysfunction (Child-Pugh B and C): Contraindicated


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Administer with a meal, without regard to fat or calorie content.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store at or below 30C (86F).

-Each fixed-dose combination tablet contains ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg.
-The manufacturer product information for ribavirin should be consulted for additional information.

-Hepatic: Baseline hepatic laboratory and clinical parameters (before starting therapy); hepatic laboratory tests (at baseline, during first 4 weeks of therapy, then as clinically indicated); ALT (if increases above baseline)

Patient advice:
-Read the US FDA-approved patient information (Medication Guide) for this drug and review the Medication Guide for ribavirin, if applicable.
-Watch for signs of liver inflammation/failure (e.g., early signs: fatigue, weakness, lack of appetite, nausea and vomiting; later signs: jaundice, onset of confusion, abdominal swelling, discolored feces); consult healthcare provider immediately if these symptoms develop.